276 related articles for article (PubMed ID: 12851613)
1. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
[TBL] [Abstract][Full Text] [Related]
2. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
4. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
[TBL] [Abstract][Full Text] [Related]
5. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
[TBL] [Abstract][Full Text] [Related]
6. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
7. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
[TBL] [Abstract][Full Text] [Related]
8. Uniform platelet activation exists before coronary stent implantation despite aspirin therapy.
Serebruany VL; Cummings CC; Malinin AI; Steinhubl SR; Gurbel PA
Am Heart J; 2001 Oct; 142(4):611-6. PubMed ID: 11579350
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
11. The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy.
Gurbel PA; Bliden KP
Thromb Res; 2003; 112(1-2):9-12. PubMed ID: 15013266
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
13. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
[TBL] [Abstract][Full Text] [Related]
15. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
16. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topol EJ; Easton D; Harrington RA; Amarenco P; Califf RM; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Granett J; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Sigmon K; Pieper K; Vallee M; Willerson JT;
Circulation; 2003 Jul; 108(4):399-406. PubMed ID: 12874182
[TBL] [Abstract][Full Text] [Related]
18. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Serebruany VL; Malinin AI; Sane DC; Jilma B; Takserman A; Atar D; Hennekens CH
Eur J Pharmacol; 2004 Sep; 499(3):315-24. PubMed ID: 15381054
[TBL] [Abstract][Full Text] [Related]
19. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
[TBL] [Abstract][Full Text] [Related]
20. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
